Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration. Liquid biopsy might allow real-time sampling of patients for PD-L1 through the course of the dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolazzo, Chiara, Raimondi, Cristina, Mancini, MariaLaura, Caponnetto, Salvatore, Gradilone, Angela, Gandini, Orietta, Mastromartino, Maria, del Bene, Gabriella, Prete, Alessandra, Longo, Flavia, Cortesi, Enrico, Gazzaniga, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995431/
https://www.ncbi.nlm.nih.gov/pubmed/27553175
http://dx.doi.org/10.1038/srep31726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995431/
https://www.ncbi.nlm.nih.gov/pubmed/27553175
http://dx.doi.org/10.1038/srep31726

Ejemplares similares